Defending Homegrown Investment: Why Dei Biopharma Strategic Factories Must Be Protected from Predatory Liquidation

Nov 16, 2026 - 19:03
 0  160
Defending Homegrown Investment: Why Dei Biopharma Strategic Factories Must Be Protected from Predatory Liquidation

The ongoing clash between Equity Bank Uganda, Equity Bank Kenya, and prominent Ugandan industrialist Dr. Mathias Magoola is far more than a routine debt-recovery dispute—it is a critical test of how the financial sector supports or stifles national manufacturing. At the heart of the standoff is a contested claim exceeding Shs148 billion ($43 million and Shs 82 billion across associated entities like Dei BioPharma and Dei Industries International), which Equity Bank is rushing to recover through the public auction of foundational industrial, medical, and commercial assets.

Yet, pushing ahead with an auction while an independent audit and crucial appeals remain pending before the courts raises profound questions about corporate fairness, banking ethics, and the protection of strategic national investments.

The Core of the Dispute: An Unsettled and Disputed Debt

Dr. Magoola’s legal team, Muwema & Co. Advocates, has rightly pointed out a glaring flaw in the banks' posture: the exact, lawful quantum of the debt has not been conclusively audited or settled. The matter is subject to a judicial framework involving reconciliation processes and active deliberations before the Court of Appeal.

When financial institutions use aggressive recovery tactics—such as 14-day vacation notices and public auction announcements—before a neutral, court-sanctioned audit has verified the legitimacy of consolidated interest charges, fees, and restructurings, it crosses the line from prudent lending into heavy-handed overreach.

Sacrificing National Industrialization for Short-Sighted Recovery

Dr. Magoola is not an ordinary debtor; he is the visionary behind Uganda’s ambitious pharmaceutical manufacturing drive—including the multi-billion Dei BioPharma project, which has drawn significant national and governmental backing (reportedly scaling past Shs723.4 billion in strategic interest) to build local capacity for medicines, vaccines, and healthcare independence in East Africa.

The assets targeted by Equity Bank include critical pillars of this ecosystem: a 20-acre industrial park in Matugga, an operational wheat milling plant in Luzira designed to generate vital operational cash flow, and a hospital property in Kitende. Dismantling or liquidating these integrated facilities prematurely does not just hurt Dr. Magoola—it inflicts a heavy blow on Uganda’s industrialization agenda, job creation, and import-substitution goals.

Equity Must Wait for Justice and Transparency

Banks have a legitimate right to recover validly owed funds, but they also have a fiduciary and social responsibility to act in good faith. Rushing to sell off multi-sector production plants while the courts are still unravelling disputed account balances looks less like standard debt recovery and more like an attempt to preempt judicial scrutiny.

Equity Bank Uganda and Equity Bank Kenya should heed the call for restraint. They ought to pause the hammer, respect the ongoing legal and appellate processes, and allow the independent audit to run its course. 

True financial partnership means nurturing homegrown enterprise through turbulence—not derailing a monumental industrial dream over a premature auction block.

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0
\